CGM‐derived efficacy and overall safety of once‐weekly insulin efsitora alfa (efsitora) relative to day of administration in adults with type 2 diabetes

Metadata

Item Type:	Article
Authors/Creators:	Martens, T. https://orcid.org/0000-0002-9858-2138 Battelino, T. https://orcid.org/0000-0002-0273-4732 Heller, S. https://orcid.org/0000-0002-2425-9565 Bhargava, A. Ji, L. https://orcid.org/0000-0003-1305-1598 Murthy, S. https://orcid.org/0000-0001-5571-7357 Threlkeld, R.J. Li, X. Murro, A.L. Syring, K. https://orcid.org/0000-0003-0126-9848 Patel, V.
Copyright, Publisher and Additional Information:	© 2026 Eli Lilly and Company and The Author(s). This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in anymedium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. http://creativecommons.org/licenses/by-nc-nd/4.0/
Keywords:	basal insulin; continuous glucose monitoring (CGM); insulin therapy; type 2 diabetes
Dates:	Submitted: 17 November 2025 Accepted: 18 December 2025 Published (online): 22 January 2026 Published: March 2026
Institution:	The University of Sheffield
Academic Units:	The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Medicine and Population Health
Date Deposited:	28 Jan 2026 11:01
Last Modified:	25 Mar 2026 12:13
Status:	Published
Publisher:	Wiley
Refereed:	Yes
Identification Number:	10.1111/dom.70419
Open Archives Initiative ID (OAI ID):	oai:eprints.whiterose.ac.uk:237038

CORE (COnnecting REpositories)